Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.

Gorzalczany Y, Gilad Y, Amihai D, Hammel I, Sagi-Eisenberg R, Merimsky O.

Cancer Lett. 2011 Nov 28;310(2):207-15. doi: 10.1016/j.canlet.2011.07.002. Epub 2011 Jul 14.

PMID:
21807458
2.

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.

Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.

Cancer Chemother Pharmacol. 2012 Nov;70(5):707-16. doi: 10.1007/s00280-012-1946-3. Epub 2012 Sep 2.

PMID:
22941374
3.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

4.

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.

Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.

Clin Cancer Res. 2010 Oct 15;16(20):4990-5001. doi: 10.1158/1078-0432.CCR-10-0923. Epub 2010 Sep 1.

5.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
6.

The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.

Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B.

J Thorac Oncol. 2013 Jun;8(6):693-702. doi: 10.1097/JTO.0b013e31828c7210.

7.

Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.

Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.

Oncol Res. 2013;21(3):137-44. doi: 10.3727/096504013X13832473330032.

PMID:
24512728
8.

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.

BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188.

9.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

Mol Cancer Ther. 2006 Nov;5(11):2676-84.

10.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

11.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
12.

Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.

Rosetti M, Zoli W, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D, Silvestrini R.

J Cell Physiol. 2007 Sep;212(3):710-6.

PMID:
17458894
14.

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.

Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15.

PMID:
22985911
16.

Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.

Gupta P, Emdad L, Lebedeva IV, Sarkar D, Dent P, Curiel DT, Settleman J, Fisher PB.

J Cell Physiol. 2008 Jun;215(3):827-36. doi: 10.1002/jcp.21369.

PMID:
18270968
17.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

18.

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R.

Invest New Drugs. 2010 Aug;28(4):433-44. doi: 10.1007/s10637-009-9266-0. Epub 2009 Jun 5.

PMID:
19499189
19.

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.

Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF, De Luo B.

Mol Biol Rep. 2012 Apr;39(4):4971-9. doi: 10.1007/s11033-011-1293-1. Epub 2011 Dec 9.

PMID:
22160570

Supplemental Content

Support Center